High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients

Arthritis Care and Research

Volumn 57, Issue 4, 2007, Pages 619-625

  Nath, Rahul ^a   Mant, Christine ^b   Luxton, Jennifer ^a   Hughes, Graham ^a   Raju, K Shanti ^a   Shepherd, Phillip ^a   Cason, John ^b,c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

Cervical squamous intraepithelial lesions; Human papillomavirus infection; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; COLPOSCOPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOLOGY; DISEASE ASSOCIATION; DISEASE COURSE; DNA SEQUENCE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SQUAMOUS INTRAEPITHELIAL LESION; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VIRUS LOAD;

ADOLESCENT; ADULT; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 34248526065     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22667     Document Type: Article

References (36)

1. Stichweh D, Pascual V. Autoimmune mechanisms in children with systemic lupus erythematosus [review]. Curr Rheumatol Rep 2005;7:421-6.
2. Nyberg G, Eriksson O, Westberg NG. Increased incidence of cervical atypia in women with systemic lupus erythematosus, treated with chemotherapy. Arthritis Rheum 1981;24:648-50.
3. Blumenfeld Z, Lorber M, Yoffe N, Scharf Y. Systemic lupus erythematosus: predisposition for uterine cervical dysplasia. Lupus 1994;3:59-61.
4. Bateman H, Yazici Y, Leff L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 2000;9:542-4.
5. Dhar JP, Kmak D, Bhan R, Pishorodi L, Ager J, Sokol RJ. Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. Gynecol Oncol 2001;82:4-6.
6. Bernatsky S, Ramsey-Goldman R, Gordon C, Joseph L, Boivin JF, Rajan R, et al. Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology (Oxford) 2004;43:1386-9.
7. Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, et al. Increased incidence of SIL in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004;31:1763-7.
8. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 2005;53:781-4.
9. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relationship between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
10. Munoz N. Human papillomavirus and cancer: the epidemiological evidence [review]. J Clin Virol 2000;19:1-5.
11. Cavuslu S, Goodlad J, Hobbs C, Connor AM, Best JM, Cason JS. Relationship between human papillomavirus infection and overexpression of p53 in cervical carcinomas and lymph node metastases. J Med Virol 1997;53:111-7.
12. Johansson E, Pyrhonen S, Rostila T. Warts and wart virus antibodies in patients with systemic lupus erythematosus. Br Med J 1977;1:74-6.
13. Tam LS, Chan AY, Chan PK, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus. Arthritis Rheum 2004;50:3619-25.
14. Burghardt E. Microinvasive carcinoma in gynaecological pathology [review]. Clin Obstet Gynaecol 1984;11:239-57.
15. Cox MF, Meanwell CA, Maitland NJ, Blackledge G, Scully C, Jordan JA. Human papillomavirus type-16 homologous DNA in normal human ectocervix [letter]. Lancet 1986;2:157-8.
16. De Villiers EM, Wagner D, Schneider A, Wesch H, Miklaw H, Wahrendorf J, et al. Human papillomavirus infections in women with and without abnormal cervical cytology. Lancet 1987;2:703-6.
17. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Eng J Med 1988;338:423-8.
18. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
19. Matsumoto K, Yoshikawa H, Nakagawa S, Tang X, Yasugi T, Kawana K, et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV 16) variants in Japanese population. Cancer Lett 2000;156:159-65.
20. Bible JM, Mant C, Best JM, Kell B, Starkey WG, Shanti Raju K, et al. Cervical lesions are associated with human papillomavirus type 16 intratypic variants that have high transcriptional activity and increased usage of common mammalian codons. J Gen Virol 2000;81:1517-27.
21. Ndisang D, Faulkes DJ, Gascoyne D, Lee SA, Ripley BJ, Sindos M, et al. Differential regulation of different human papilloma virus variants by the POU family transcription factor Brn-3a. Oncogene 2006;25:51-60.
22. Ryan AK, Rosenfeld MG. POU domain family values: flexibility, partnerships, and developmental codes. Genes Dev 1997;11:1207-25.
23. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
24. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anaemia. Science 1985;230:1350-4.
25. Manos M, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989;7:209-14.
26. Cavuslu S, Mant C, Starkey WG, Bible JM, Biswas C, Kell B, et al. Analytic sensitivities of hybrid capture, consensus and type-specific PCRs for the detection of human papillomavirus type 16 DNA. J Med Virol 1996;49:319-24.
27. Mant C, Kell B, Best JM, Cason J. Polymerase chain reaction protocols for the detection of DNA from mucosal human papillomavirus types -6, -11, -16, -18, -31 and -33. J Virol Methods 1997;66:169-78.
28. National Center for Biotechnology Information. BLAST. URL: http://www.ncbi.nlm.nih.gov/BLAST.
29. National Center for Biotechnology Information. PubMed. URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi.
30. European Bioinfomatics Institute. ClustalW. URL: http://www.ebi.ac.uk/ clustalw.
31. Fisher's exact test. URL: http://www.matforsk.no/ola/fisher.htm.
32. GraphPad Software. Quickcalcs online calculators for scientists. URL: http://www.graphpad.com/quickcalcs/.
33. Seedorf K, Krammer G, Durst M, Suhai S, Rowekamp WG. Human papillomavirus type 16 DNA sequence. Virology 1985;145:181-5.
34. Si-Mohamed A, Ndjoyi-Mbiguino A, Cuschieri K, Onas IN, Colombet I, Ozouaki F, et al. High prevalence of high-risk oncogenic human papillomaviruses harboring atypical distribution in women of childbearing age living in Libreville, Gabon. J Med Virol 2005;77:430-8.
35. National Health Service. Cancer screening programmes. URL: http://www.cancerscreening.nhs.uk.
36. Matteson EL, Hickney AR, Maguire L, Tilson HH, Urowitz M. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 1991;18:809-14.